



This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------------------------------|---------------------------|---|--|--|
| Cancer | | | | |
| Non-small cell lung cancer (NSCLC) | MicroRNA-21 (miR- 21) | Cell culture and mouse studies suggest that inhibiting miR-21 could help treat NSCLC. In a mouse model of K-Ras mutant NSCLC, animals lacking miR-21 had a lower tumor load than wild-type mice. In a K-Ras mutant cell line, deletion of miR-21 increased doxorubicin-induced apoptosis compared with that in similarly treated control cells. Next steps include pharmacological inhibition of miR-21 in a NSCLC mouse model. | Unpatented; licensing status undisclosed | Hatley, M.E. et al. Cancer Cell; published online Sept. 13, 2010; doi:10.1016/j.ccr.2010.08.013 Contact: Eric N. Olson, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: eric.olson@utsouthwestern.edu |
| | | SciBX 3(38); doi:10.1038/scibx.2010.1149 Published online Sept. 30, 2010 | | |